Cubist antibiotic tedizolid fares well in FDA review
This article was originally published in Scrip
Executive Summary
Briefing documents posted ahead of the 31 March meeting of the FDA's Anti-Infective Drugs Advisory Committee revealed Cubist Pharmaceuticals garnered a fairly clean review of its experimental antibiotic tedizolid phosphate (TR-701) from US regulators, with the agency's scientists only raising some slight concerns about safety.